logo-loader
viewCeapro Inc.

Ceapro to begin clinical trials for beta glucan to treat high cholesterol

Ceapro Inc (CVE: CZO) CEO Gilles Gagnon tells Proactive Investors the company will soon begin enrollment in clinical trials of its cholesterol-fighting beta glucan.

Meanwhile, the Canadian-based biotech company's recent positive findings indicate its PGX Technology can be used as a delivery system for use on the skin or as a fast-acting oral drug.

Quick facts: Ceapro Inc.

Price: 0.7 CAD

TSX-V:CZO
Market: TSX-V
Market Cap: $54.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpine 4 Technologies growth continues in Q-1 of 2020 with a nice jump in...

Alpine 4 Technologies (OTC: ALPP) CEO Kent Wilson joined Steve Darling from Proactive Vancouver to share news about the company’s 1st Quarter financial numbers that some very good growth. Wilson shares the numbers and some of the highlights. Wilson also talked about the company’s strategy when...

59 minutes ago

2 min read